This is a competing renewal application for the Rheumatic Diseases Core Center (RDCC) at Washington University. The overall goal of the RDCC is to enhance multidisciplinary study of the rheumatic diseases. To achieve these goals, the following Specific Aims are proposed: 1) Support ongoing funded research;2) Facilitate direct study of rheumatic disease models;3) Enhance interest in the rheumatic diseases;4) Expedite translational research in the rheumatic diseases (a new Specific Aim);and 5) Foster development of junior faculty. To address these Specific Aims, an Administrative Core is proposed to provide leadership, management, and infrastructure. An Enrichment Program is proposed consisting of outside speaker support, and a Pilot and Feasibility (P/F) Program in which projects by junior faculty are supported. Two research cores are proposed. A Genetics Core will consist of a Transgenic and Knockout Mouse Facility, a Speed Congenics Facility, and a new Human Genomics and Bioinformatics Facility. A Protein Core will consist of a Hybridoma Center, and a Protein Production and Purification Facility. Over the current funding period, these cores have demonstrated productivity and are testing new protocols that are now ready for use by RDCC investigators. All core facilities propose to test additional services that will be added in the future. Thus, the RDCC will provide not only a means to enhance ongoing research but also is organized in a manner to facilitate the efforts of investigators in their study of rheumatic diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
5P30AR048335-12
Application #
8314004
Study Section
Special Emphasis Panel (ZAR1-MLB (M1))
Program Officer
Mao, Su-Yau
Project Start
2001-09-28
Project End
2016-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
12
Fiscal Year
2012
Total Cost
$552,964
Indirect Cost
$208,000
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Watson, Rachael; Wearmouth, Emma; McLoughlin, Amy-Claire et al. (2015) Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 63:287-96
Krupnick, Alexander Sasha; Lin, Xue; Li, Wenjun et al. (2014) Central memory CD8+ T lymphocytes mediate lung allograft acceptance. J Clin Invest 124:1130-43
Choi, Jayoung; Park, Sunmin; Biering, Scott B et al. (2014) The parasitophorous vacuole membrane of Toxoplasma gondii is targeted for disruption by ubiquitin-like conjugation systems of autophagy. Immunity 40:924-35
Salinas, Nichole D; Paing, May M; Tolia, Niraj H (2014) Critical glycosylated residues in exon three of erythrocyte glycophorin A engage Plasmodium falciparum EBA-175 and define receptor specificity. MBio 5:e01606-14
Lyzogubov, Valeriy; Wu, Xiaobo; Jha, Purushottam et al. (2014) Complement regulatory protein CD46 protects against choroidal neovascularization in mice. Am J Pathol 184:2537-48
Park, Hyon Ju; Guariento, Mara; Maciejewski, Mateusz et al. (2014) Using mutagenesis and structural biology to map the binding site for the Plasmodium falciparum merozoite protein PfRh4 on the human immune adherence receptor. J Biol Chem 289:450-63
Siebrasse, Erica A; Nguyen, Nang L; Smith, Colin et al. (2014) Immunohistochemical detection of KI polyomavirus in lung and spleen. Virology 468-470:178-84
Yu, Yi; Triebwasser, Michael P; Wong, Edwin K S et al. (2014) Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration. Hum Mol Genet 23:5283-93
Gubin, Matthew M; Zhang, Xiuli; Schuster, Heiko et al. (2014) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515:577-81
Ferris, Stephen T; Carrero, Javier A; Mohan, James F et al. (2014) A minor subset of Batf3-dependent antigen-presenting cells in islets of Langerhans is essential for the development of autoimmune diabetes. Immunity 41:657-69

Showing the most recent 10 out of 69 publications